The decision came two days before Spain was to resume use of the AstraZeneca vaccine after the EU's drug regulator deemed the jab "safe and effective".
The Geneva-based body urged vigilance as case numbers rise in several regions, including Europe, driven partly by virus variants that transmit more easily.
The trial results, primarily generated in the United States but also in Chile and Peru, included a 79% efficacy in preventing symptomatic COVID-19, and showed no increased risk of a rare form of blood clots that has caused concern in parts of Europe.
Britain's Medicines and Healthcare products Regulatory Agency concluded at the time that a 12-week gap between doses was the key to achieving the highest efficacy, of around 80%.
Maharashtra, India's most industrialised state and home to its financial capital Mumbai, has been accounting for more than 60% of the country's total cases after a full-scale reopening of its economy unleashed a second wave of infections late last month.
The self-ruled democratic island has signed contracts to purchase 10 million AstraZeneca doses, as well as around 5 million doses each from Moderna and the international Covax scheme.
France was one of more than a dozen European Union states that suspended use of the Anglo-Swedish vaccine this week following reports of blood clotting in a small number of recipients of the shot.
The EU's drug watchdog (EMA) on Thursday said it was convinced the benefits of the AstraZeneca vaccine outweighed the risks.
The Philippines, which has the second-highest number of COVID-19 cases and deaths in Southeast Asia, is facing a renewed wave of infections, with nearly 20,000 new cases reported in the past four days.